A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers
Giandomenico Roviello(University of Florence), Daniele Generali(University of Trieste), Chiara Senti(Istituti Ospitalieri di Cremona), Maria Rosa Cappelletti(University of Trieste), Sandra Sigala(Brescia University), Carla Strina(Istituti Ospitalieri di Cremona), Laura Zanotti(Istituti Ospitalieri di Cremona), Manuela Milani(Humanitas University), Angela Gobbi(Istituti Ospitalieri di Cremona), Alberto Bottini(University of Genoa)
Cited by 7
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268